Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011)

Diagnostic Microbiology and Infectious Disease

Volumn 78, Issue 4, 2014, Pages 443-448

  Sader, Helio S ^a   Farrell, David J ^a   Flamm, Robert K ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Antimicrobial resistance; Gram negative pathogens; Intensive care units

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; TOBRAMYCIN;

ACINETOBACTER; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CONTROLLED STUDY; ENTEROBACTER; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; NONHUMAN; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SERRATIA; TREND STUDY; UNITED STATES;

ANTIMICROBIAL RESISTANCE; GRAM-NEGATIVE PATHOGENS; INTENSIVE CARE UNITS;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; EUROPE; HOSPITALS; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; PREVALENCE; UNITED STATES;

EID: 84895871565     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.11.025     Document Type: Article

References (28)

1. Agodi A., Voulgari E., Barchitta M., Politi L., Koumaki V., Spanakis N., et al. Containment of an outbreak of KPC-3-producing Klebsiella pneumoniae in Italy. J Clin Microbiol 2011, 49:3986-3989.
2. Boucher H.W., Talbot G.H., Benjamin D.K., Bradley J., Guidos R.J., Jones R.N., et al. 10 × '20 Progress-Development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013, 56:1685-1694.
3. Castanheira M., Farrell S.E., Krause K.M., Jones R.N., Sader H.S. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine United States census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicro Agents Chemother 2014, (submitted).
4. Centers for Disease Control and Prevention (CDC) Guidance for control of carbapenem-resistant Enterobacteriaceae (CRE) Available at, Accessed July 2013. http://www.cdc.gov/hai/pdfs/cre/CRE-guidance-508.pdf.
5. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard (M07-A9) 2012, CLSI, Wayne, PA. ninth edition.
6. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: 23rd informational supplement (M100-S23) 2013, CLSI, Wayne, PA.
7. Croughs P.D., Li B., Hoogkamp-Korstanje J.A., Stobberingh E. Thirteen years of antibiotic susceptibility surveillance of Pseudomonas aeruginosa from intensive care units and urology services in the Netherlands. Eur J Clin Microbiol Infect Dis 2013, 32:283-288. Antibiotic Resistance Surveillance Group.
8. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0, January 2013 Available at, Accessed January 2, 2013. http://www.eucast.org/clinical_breakpoints/.
9. European Centre for Disease Prevention, Control.(ECDC) Risk assessment on the spread of carbapenemase-producing Enterobacteriaceae (CPE) through patient transfer between healthcare facilities, with special emphasis on cross-border transfer Accessed. http://ecdc.europa.eu/en/publications/Publications/110913_Risk_assessment_resistant_CPE.pdf.
10. Fraimow H.S., Tsigrelis C. Antimicrobial resistance in the intensive care unit: mechanisms, epidemiology, and management of specific resistant pathogens. Crit Care Clin 2011, 27:163-205.
11. Glasner C., Albiger B., Buist G., Tambic Andrasevic A., Canton R., Carmeli Y., et al. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill 2013, 18.
12. Hanberger H., Arman D., Gill H., Jindrak V., Kalenic S., Kurcz A., et al. Surveillance of microbial resistance in European Intensive Care Units: a first report from the Care-ICU programme for improved infection control. Intensive Care Med 2009, 35:91-100.
13. Kaiser R.M., Castanheira M., Jones R.N., Tenover F., Lynfield R. Trends in Klebsiella pneumoniae carbapenemase-positive K. pneumoniae in US hospitals: report from the 2007-2009 SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2013, 76:356-360.
14. Kitchel B., Rasheed J.K., Patel J.B., Srinivasan A., Navon-Venezia S., Carmeli Y., et al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 2009, 53:3365-3370.
15. Martin S.J., Yost R.J. Infectious diseases in the critically ill patients. J Pharm Pract 2011, 24:35-43.
16. Morata L., Cobos-Trigueros N., Martinez J.A., Soriano A., Almela M., Marco F., et al. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2012, 56:4833-4837.
17. Nordmann P., Naas T., Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011, 17:1791-1798.
18. Peleg A.Y., Hooper D.C. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 2010, 362:1804-1813.
19. Peralta G., Sanchez M.B., Garrido J.C., De Benito I., Cano M.E., Martinez-Martinez L., et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J Antimicrob Chemother 2007, 60:855-863.
20. Retamar P., Portillo M.M., Lopez-Prieto M.D., Rodriguez-Lopez F., de Cueto M., Garcia M.V., et al. Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. Antimicrob Agents Chemother 2012, 56:472-478.
21. Riou M., Carbonnelle S., Avrain L., Mesaros N., Pirnay J.P., Bilocq F., et al. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of intensive care unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. Int J Antimicrob Agents 2010, 36:513-522.
22. Rosenthal V.D., Bijie H., Maki D.G., Mehta Y., Apisarnthanarak A., Medeiros E.A., et al. International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009. Am J Infect Control 2012, 40:396-407.
23. Sievert D.M., Ricks P., Edwards J.R., Schneider A., Patel J., Srinivasan A., et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013, 34:1-14.
24. Swaminathan M., Sharma S., Poliansky Blash S., Patel G., Banach D.B., Phillips M., et al. Prevalence and risk factors for acquisition of carbapenem-resistant enterobacteriaceae in the setting of endemicity. Infect Control Hosp Epidemiol 2013, 34:809-817.
25. Tygacil® Package Insert 2012, Wyeth Pharmaceuticals, Philadelphia, PA, Available at, Accessed January 2013. http://www.tygacil.com.
26. Vincent J.L., Rello J., Marshall J., Silva E., Anzueto A., Martin C.D., et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329.
27. Walsh T.R. Emerging carbapenemases: a global perspective. Int J Antimicrob Agents 2010, 36(Suppl 3):S8-S14.
28. Zavascki A.P., Carvalhaes C.G., Picao R.C., Gales A.C. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 2010, 8:71-93.